除预付款外,Aduro将获得每件产品约6.2亿美元的开发和商业阶段性付款,以及另外的专利使用费。礼来将负责全球商业化所有成本,该交易不会导致礼来2018年非GAAP每股收...查看全文
Pharmayang2018-03-19 04:39
$Aduro BioTech Inc(ADRO)$ 看了他家的pipeline,主要是STING,和其他三家Pharma合作。现在和MRK的keytruda联用也开始了,target CD27 receptor增加T cell和NK cell数量。值得关注。
他家的cash很多,短期估计不会增发了。现在的价格还行。下半年有不少catalyst。查看全文
$Aduro BioTech Inc(ADRO)$ 8-K Current report, items 5.03, 5.07, 7.01, and 9.01 Accession Number: 0001193125-20-261293 Act: 34 Size: 202 KB 网页链接
$Aduro BioTech Inc(ADRO)$ 8-K Current report, item 7.01 Accession Number: 0001193125-20-252523 Act: 34 Size: 66 KB 网页链接
$Aduro BioTech Inc(ADRO)$ 425 Prospectuses and communications, business combinations Accession Number: 0001193125-20-252525 Act: 34 Size: 26 KB 网页链接
$Aduro BioTech Inc(ADRO)$ 8-K Current report, item 8.01 Accession Number: 0001193125-20-249542 Act: 34 Size: 77 KB 网页链接
$Aduro BioTech Inc(ADRO)$ 425 Prospectuses and communications, business combinations Accession Number: 0001193125-20-249551 Act: 34 Size: 36 KB 网页链接
$Aduro BioTech Inc(ADRO)$ 内部交易: 2020-09-15,SVP, GC and Secretary,Ferber Celeste ,卖出,2396普通股, $2.39
$Aduro BioTech Inc(ADRO)$ 内部交易: 2020-09-15,Chief Legal Officer,Templeman Blaine ,卖出,12369普通股, $2.39
$Aduro BioTech Inc(ADRO)$ 内部交易: 2020-09-15,总裁 and CEO,ISAACS STEPHEN T ,卖出,32481普通股, $2.39
$Aduro BioTech Inc(ADRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001567619-20-016852 Size: 5 KB 网页链接
$Aduro BioTech Inc(ADRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001567619-20-016853 Size: 5 KB 网页链接